目的 探討復方苦參注射液聯(lián)合順鉑治療非小細胞肺癌惡性胸腔積液的臨床療效。方法 選取2018年3月—2022年3月天津市寶坻區(qū)人民醫(yī)院胸外科收治的68例非小細胞肺癌伴惡性胸腔積液患者，按隨機數(shù)字表法分為治療組和對照組，每組各34例。對照組給予注射用順鉑40 mg/次、地塞米松10 mg/次，用生理鹽水50 mL稀釋后，通過胸腔閉式引流管進行胸腔緩慢注入。治療組在對照組的治療基礎上給予復方苦參注射液30 mL，所有藥物與生理鹽水共加至50 mL，腔內(nèi)緩慢注入。注入藥物后胸腔閉式引流管夾閉24 h，1次/周，連用3次為一療程。兩組治療1個療程。觀察兩組患者的臨床療效，比較生活質(zhì)量改善情況，胸腔積液中癌胚抗原（CEA）、血管內(nèi)皮生長因子（VEGF）水平和不良反應發(fā)生情況。結果 治療后，治療組總有效率為79.41%，顯著高于對照組的55.88%（P＜0.05）。治療后，兩組患者VEGF、CEA水平較治療前均顯著降低（P＜0.05）；且治療組較對照組降低更為明顯（P＜0.05）。生活質(zhì)量方面，治療組總有效率是91.18%，顯著優(yōu)于對照組的70.59%（P＜0.05）。治療后，治療組胃腸道反應和骨髓抑制發(fā)生率明顯低于對照組（P＜0.05）。結論 復方苦參注射液聯(lián)合順鉑治療非小細胞肺癌惡性胸腔積液具有較好的臨床療效，可提升患者的生活質(zhì)量，減少藥物的不良反應。

Objective To observe the clinical efficacy of Compound Kushen Injection combined with cisplatin in treatment of non-small cell lung cancer malignant pleural effusion. Methods A total of 68 patients with non-small cell lung cancer with malignant pleural effusion admitted to the Thoracic Surgery Department of Tianjin Baodi District People's Hospital from March 2018 to March 2022 were selected and divided into treatment group and control group according to random number table method, with 34 cases in each group. Patients in the control group were iv administered with Cisplatin for injection, 40 mg/time, dexamethasone 10 mg/time, diluted with 50 mL normal saline, and slowly injected into the chest through a closed thoracic drainage tube. Patients in the treatment group were iv administered with 30mL of Compound Kushen Injection on the basis of the control group, all drugs were added to 50 mL normal saline and injected into the cavity slowly. After drug injection, the closed thoracic drainage tube was clamped for 24 h, once a week, for 3 consecutive times as a course. Two groups were treated for 1 course. The clinical efficacy of the two groups of patients was observed, and the improvement of quality of life, the levels of carcinoembryonic antigen (CEA) and vascular endothelial growth factor (VEGF) in pleural effusion and the occurrence of adverse reactions were compared. Results After treatment, the total effective rate of the treatment group was 79.41%, which was significantly higher than that of the control group (55.88%) (P < 0.05). After treatment, VEGF and CEA levels in two groups were significantly decreased compared with those before treatment (P < 0.05). The decrease was more obvious in the treatment group than that in the control group (P < 0.05). In terms of quality of life, the total effective rate of the treatment group was 91.18%, which was significantly better than that of the control group (70.59%) (P < 0.05). After treatment, the incidence of gastrointestinal reaction and myelosuppression in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Compound Kushen Injection combined with cisplatin has good clinical effect in treatment of advanced non-small cell lung cancer malignant pleural effusion, and can improve the life quality of patients, reduce adverse reactions, which has important application value in clinical treatment.

R979.1